Conference Coverage

Surgical Margins and Other Important Prognostic Factors in Dedifferentiated Liposarcoma Survival

Author and Disclosure Information

 

Background: Liposarcoma is the most common malignant soft tissue sarcoma (STS). Surgical resection is the most utilized therapeutic option. In this study, we aim to explore the effects of varying degrees of surgical margins on survival in patients with dedifferentiated liposarcoma (DDLPS).

Methods: The National Cancer Database (NCDB) was used to select patients with DDLPS to determine if surgical margins and other variables were associated with decreased overall survival after accounting for age, gender, race, Charlson-Deyo score, anatomic site, treatment approach, tumor size, tumor grade, and presence of metastases through multivariable analysis.

Results: Of the 1004 selected patients, 64.4% were male, 87.0% were white, and the median age was 63 years. About 95% had no metastases at the time of diagnosis, and 91.5% had high grade liposarcoma. For the status of surgical margins, 50.8% had no residual tumors, 26.1% had microscopic residual tumors, 4.3% had macroscopic residual tumors. In general, the risk of death was higher for older males (25.8% increased risk of mortality) and those with metastases (312.9% increased risk of mortality) as well as patients with high grade liposarcoma (112.4% increased risk of mortality). Patients with macroscopic residual tumors in comparison to those with no residual tumors had a 96.7% increased risk of death (HR 95% CI:1.24 to 3.13; P=0.004).

Conclusion: Older age, presence of metastasis, male patients, retroperitoneal/abdomen primary site, highgrade tumors, and macroscopic or residual tumor present after surgery lead to an increased risk of mortality. These outcomes highlight the importance and benefits of negative or complete surgical margins as prognostic indicators for patients with DDLPS, especially considering that resection is the most commonly utilized therapeutic option. The NCDB contains about 70% of cancer incidents within the US, therefore a future study incorporating the Surveillance, Epidemiology, and End Results (SEER) registry could enhance and possibly add to the results brought forth by this study.

Recommended Reading

Immune Checkpoint Inhibitors for Urothelial Cancer: An Update on New Therapies (FULL)
AVAHO
2018: A banner year for hematology drug approvals
AVAHO
Improving VTE Risk Prediction for Patients With Multiple Myeloma
AVAHO
What I learned from Navy SEALs about resilience
AVAHO
How to review scientific literature
AVAHO
Treating lymphoma in patients with HIV
AVAHO
Use of Mobile Messaging System for Self-Management of Chemotherapy Symptoms in Patients with Advanced Cancer (FULL)
AVAHO
Treatment Facility: An Important Prognostic Factor for Dedifferentiated Liposarcoma Survival (FULL)
AVAHO
Nivolumab-Induced Hypothyoidism With Consequent Hypothyroid Related Myopathy
AVAHO
How Long Should it Take to Get a Pathology Diagnosis?
AVAHO